Semaglutide Explained: What It Is and How It Works

Few medications have entered public conversation as quickly, or as noisily, as semaglutide. It is the active drug behind brand names that have become household words — Ozempic, Wegovy, Rybelsus — and behind a wave of weight-loss results that genuinely surprised the field that produced them. But the noise has not made the drug easier to understand. People know the brand names without knowing they are the same molecule, hear about the weight loss without understanding the mechanism, and encounter the side effects without the context that makes them predictable. This page is a straightforward profile of the drug itself: what semaglutide is, how it works, what the evidence shows, and who it is for.

For the wider scientific context — how this whole class of medications emerged, and how it sits alongside the dual agonist tirzepatide — the GLP-1 science pillar guide provides the fuller map. This page narrows the focus to one molecule.

What Semaglutide Actually Is

Semaglutide is a GLP-1 receptor agonist. That phrase contains most of what you need to know. GLP-1 — glucagon-like peptide-1 — is a hormone the gut releases after meals; an "agonist" is a molecule that activates a receptor the way the natural signal would. Semaglutide is, in effect, an engineered, long-lasting copy of a hormone the body already makes and already uses to coordinate eating and blood sugar.

The reason it had to be engineered rather than simply administered is a problem of survival. Native GLP-1 is destroyed within about two minutes of release by an enzyme called DPP-4, far too fast to work as a medication. Semaglutide solves this with targeted changes to the molecule — amino-acid substitutions that block enzymatic breakdown and a fatty-acid chain that lets it bind to albumin in the blood, the protein that carries it slowly through circulation. The result is a molecule that lasts roughly a week per dose, which is why the injectable forms are taken once weekly rather than several times a day. As Daniel Drucker's 2018 synthesis in Cell Metabolism describes, this engineering is what turned a fleeting gut hormone into a durable therapy.

It is worth being clear about what semaglutide is not. It is not a stimulant, not an amphetamine derivative, and not a "fat burner." It does not speed up the metabolism or chemically dissolve fat. It is a hormone analogue that changes appetite. Almost every effect it produces — intended and unintended — follows from that single fact.

The Brands: Ozempic, Wegovy, and Rybelsus

Much of the public confusion around semaglutide comes from branding. The same molecule is sold under different names, at different doses, for different approved uses. Organising the field by what is actually in the syringe or tablet clears most of it up.

• Ozempic is injectable semaglutide approved for type 2 diabetes. It was the first semaglutide brand to market, approved in 2017.
• Wegovy is the same injectable molecule at higher doses, approved specifically for weight management. It is semaglutide titrated up to a 2.4mg weekly maintenance dose.
• Rybelsus is an oral tablet form of semaglutide for type 2 diabetes — notable because delivering a peptide by mouth, where digestive enzymes would normally destroy it, required a specialised absorption-enhancing formulation taken daily on an empty stomach.

Because Ozempic and Wegovy are the same drug at different doses and labels, a great deal of patient confusion centres on the distinction between them. That comparison is unpacked in detail in Ozempic versus Wegovy. The short version: when prescribed for weight loss, the relevant product is usually Wegovy, dosed higher than the diabetes formulation. The molecule is identical; the dose, route, and licensed indication differ.

How Semaglutide Works

Semaglutide reduces appetite, and it does so through several channels at once rather than a single mechanism. The detailed walkthrough of the weight-loss pathway sits in how semaglutide works for weight loss; here is the working summary.

First, it slows gastric emptying. The stomach releases its contents into the small intestine more slowly, so a meal stays in the stomach longer and produces a longer-lasting sense of fullness. You feel satisfied sooner and stay satisfied longer.

Second, it acts on the hypothalamus, the brain's appetite-regulating hub. GLP-1 receptors sit on the circuits that balance hunger against satiety, and semaglutide biases that balance toward fullness — toward the signal that says enough.

Third, and most distinctively, it quiets the brain's reward response to food. Liselotte van Bloemendaal and colleagues showed in 2014, using functional MRI, that GLP-1 receptor activation reduced the response of reward-related brain regions to images of food — and that the effect was specific to food rather than a general blunting of pleasure. This is the neurobiological basis of what patients call "food noise": the persistent, intrusive mental presence of food that often quiets dramatically on the drug. Many people describe this as more meaningful than the weight loss itself, because it frees up mental bandwidth that food preoccupation had occupied for years.

Semaglutide also improves blood-sugar control, which is why it was a diabetes drug first. It amplifies insulin secretion, but only when blood glucose is elevated — a glucose-dependent action that switches off when glucose is normal, which is why it carries a relatively low risk of hypoglycaemia on its own. It also suppresses glucagon, the hormone that raises blood sugar. The weight loss and the glucose control are two outputs of the same underlying hormonal action.

What the Trials Show

Semaglutide's reputation rests on an unusually strong evidence base. The defining study is the STEP 1 trial, led by John Wilding and published in the New England Journal of Medicine in 2021. It randomised 1,961 adults with overweight or obesity, but without diabetes, to once-weekly semaglutide titrated to 2.4mg or to placebo, both with lifestyle support. Over 68 weeks, the semaglutide group lost a mean of about 14.9% of body weight, against roughly 2.4% on placebo. About 86% of those on the drug lost at least 5% of their body weight, and a substantial share reached 10%, 15%, or even 20% loss. For a non-surgical intervention, this was without precedent.

To put that in perspective: before this generation of drugs, weight-loss medications typically delivered single-digit percentage reductions, figures that kept pharmacotherapy a marginal part of obesity care. A mean loss of around 15% was not an incremental improvement; it was a different order of magnitude. What this looks like week to week, and the realistic range of individual outcomes, is covered in weight loss on semaglutide.

For context on where semaglutide sits within its class, the dual GLP-1/GIP agonist tirzepatide produced even larger average losses — about 21% on its highest dose in the SURMOUNT-1 trial led by Ania Jastreboff in 2022. Semaglutide remains, however, the most widely used and most extensively studied agent, and the benchmark against which newer drugs are measured.

Two caveats run through all of this. First, the weight loss was achieved while taking the medication — the trials describe what the drug does during treatment, not after. Second, averages conceal wide individual variation: some people lose a great deal, others relatively little, and a minority do not respond meaningfully. The trials establish what is possible at the population level, not what any one person should expect.

Dosing: Why It Starts Low

Semaglutide is never started at its full therapeutic dose. Treatment begins low and is stepped up over weeks or months — a process called titration. The injectable weight-management schedule, for example, typically starts at 0.25mg weekly and climbs in stages toward the 2.4mg maintenance dose, with each step held for around four weeks. The full schedule is laid out in the semaglutide dosing schedule.

The reason for this slow ramp is tolerability. The same slowed gastric emptying that produces fullness also produces nausea, particularly early in treatment before the body has adapted. Titration gives the gastrointestinal system time to adjust at each dose before the next increase, keeping the adaptation ahead of the dose. Rushing or skipping titration steps is one of the most common reasons people experience side effects severe enough to make them stop. The schedule is not bureaucratic caution; it is the main tool for making the drug livable.

Side Effects

Semaglutide's side-effect profile follows directly from its mechanism, which makes it relatively predictable. The most common effects by far are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and a general early fullness that occasionally tips into discomfort. In STEP 1 these were the dominant adverse events, generally mild to moderate, and only a small minority discontinued because of them. Most people find the nausea settles substantially over weeks as the body adapts. The expected arc — when symptoms appear, peak, and fade — is mapped in the GLP-1 side effects timeline.

These effects are managed largely through how people eat: smaller meals, eaten more slowly, with less high-fat food (which empties especially slowly), and adequate hydration to address both nausea and constipation. One consequence of eating much less deserves particular attention — the risk of inadequate protein, which during weight loss accelerates the loss of lean muscle alongside fat. Clinicians working with the drug emphasise deliberate protein intake and resistance training to protect muscle.

It is also worth noting what semaglutide does not typically cause. It is not a stimulant, so it does not produce the racing heart, jitteriness, or sleep disruption that defined older appetite suppressants. The appetite reduction arrives quietly, as diminished interest in food rather than a revved-up feeling. Rarer but more serious concerns exist and are part of the clinical risk assessment — pancreatitis, gallbladder disease, and a theoretical thyroid C-cell tumour signal from rodent studies that makes the drug contraindicated in people with a personal or family history of medullary thyroid carcinoma. These are uncommon, but they are why semaglutide is a prescription medicine evaluated by a clinician rather than something taken casually.

What Happens If You Stop

For many people considering semaglutide, the most consequential question is what happens after stopping, and the honest answer is uncomfortable: for most people, much of the lost weight returns. The clearest evidence comes from the STEP 4 trial, led by Domenica Rubino in 2021, which gave everyone semaglutide for twenty weeks, then randomised participants to continue or switch to placebo. The continuation group kept losing weight; the placebo group regained roughly two-thirds of what they had lost over the following year. Wilding's 2022 STEP 1 trial extension found the same pattern after the drug was withdrawn.

This is not a flaw peculiar to semaglutide. It reflects the biology of body weight. As Priya Sumithran's 2011 work documented, after weight loss the body mounts a coordinated, lasting defence — elevated hunger hormones, suppressed satiety signals, and, as Rudolph Leibel's 1995 research showed, a measurable drop in energy expenditure. Semaglutide counters that defence for as long as it is present; when withdrawn, the defence reasserts itself, much as blood pressure rises again when antihypertensive medication is stopped. This is why semaglutide is increasingly framed as a treatment for a chronic condition rather than a time-limited course.

Who Semaglutide Is For

Eligibility for the weight-management indication is defined primarily by body mass index and associated health conditions. The typical thresholds are a BMI of 30 or higher, or 27 or higher in the presence of at least one weight-related condition — type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, or dyslipidaemia among them. For type 2 diabetes specifically, the criteria differ and centre on glucose control rather than weight. The specifics vary by brand, dose, country, and indication.

The broader rationale is that at these thresholds, dysregulated appetite and metabolic biology contribute enough to a person's weight that behavioural change alone reliably underperforms — not for lack of effort, but because willpower is being asked to override a hormonal current actively defending the higher weight. Semaglutide works by countering that current. For a wider view of where it fits among the other agents and the surrounding research, the GLP-1 science cluster collects the related explainers in one place.

What semaglutide is, in the end, is a well-studied tool that works for as long as it is used, addressing the biology of appetite rather than the willpower of the person. It is not a cure, not a shortcut, and not without trade-offs — but for many people it does something no previous medication reliably did. Whether it is the right tool in any individual case is a decision for a clinician, weighing benefits, side effects, cost, and goals together. This page is education, not medical advice.